Researchers are testing whether the Clarity ctDNA test can reliably identify patients who do just as well long term with less chemotherapy.

More than 5 years after the American Society of Clinical Oncology warned of emerging disparities in precision medicine, ...

The "Genomic Reference Materials and Controls Systems Market: Focus on Product Type, Application, End User, and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to ...

Foresight Diagnostics Inc., a Boulder-based cancer diagnostics company that specialized in the development of ultra-sensitive minimal residual disease, or MRD, detection, recently expanded its ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions.

Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cance ...

BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced today the publication of a peer-reviewed study in Nature ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib ...

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...

Discover how ctDNA revolutionizes multiple myeloma monitoring, tracking disease progression, and improving personalized ...